Statin medications are recommended for patients who have not achieved low-density lipoprotein cholesterol (LDL-C) goals through lifestyle modifications. The objective of this retrospective observational study was to examine statin medication usage patterns and the relationship with LDL-C goal levels (according to Adult Treatment Panel III guidelines) among a cohort of employees of a major financial services corporation.
From 1995 to 2004, a total of 1607 executives participated in a periodic health examination program. An index date was assigned for each study participant (date of their exam) and statin medication usage was determined from the pharmacy claims database for 365 days before the index date. Patients were identified as adherent to statins if the medication possession ratio was ≥80%.
In all, 150 (9.3%) executives filled at least 1 statin prescription in the 365 days prior to their exam. A total of 102 statin users (68%) were adherent to statin medication. Among all executives who received statin treatment, 70% (odds ratio [OR] = 2.30, 95% confidence interval [CI] = 1.82, 2.90) achieved near-optimal (<130 mg/dL) and 30% (OR = 1.78, 95% CI = 1.15, 2.76) achieved optimal (<100 mg/dL) LDL-C goals, which is significantly higher than the rates among statin nonusers (55% and 21%). Adherent statin users were more likely to achieve recommended near-optimal LDL-C goals compared to statin nonusers (overall P = 0.002; adherent: OR = 2.75, 95% CI = 1.662, 4.550), while nonadherent statin users were more likely to achieve the optimal goal compared to statin nonusers (OR = 2.223; CI = 1.145, 4.313).
Statin usage was associated with improvements in LDL-C goal attainment among executives who participated in a periodic health examination. Appropriate statin medication adherence should be encouraged in working populations in order to achieve LDL-C goals. (Population Health Management 2010;13:1–8)
Get full access to this article
View all access options for this article.
References
1.
Centers for Disease Control and Prevention, Chronic Disease Prevention and Health Promotion. Heart disease and stroke prevention. http://www.cdc.gov/nccdphp/publications/AAG/dhdsp.htm. 2008October.
2.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (ATP III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III) final report. Circulation, 2002; 106:3143–3421.
3.
NissenSE, TuzcuEM, SchoenhagenPet al.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 291:1071–1080.
4.
CannonCP, BraunwaldE, McCabeCHet al.Intensive and moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med, 2004; 350:1495–1504.
5.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet, 2002; 360:7–22.
6.
ShepherdJ, CobbeSM, FordIet al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med, 1995; 333:1301–1307.
7.
LawMR, WaldNJ, RudnickaAR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003; 326:1423–1430.
8.
DownsJR, ClearfieldM, WeisSet al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels; results of AFCAPS/TexCAPS. JAMA, 1998; 279:1615–1622.
9.
SeverPS, DublofB, PoulterNRet al. Prevention of cornonary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a muticentre randomized controlled trial. Lancet, 2003; 361:1149–1158.
GoldbergKC, MelnykSD, SimelDL. Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol. Am J Manag Care, 2007; 13:530–534.
12.
McBrideP, SchrottHG, PlaneMB, UnderbakkeG, BrownRL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med, 1998; 158:1238–1244.
13.
PearsonTA, LaurovaI, ChuH, KafonekS. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein in cholesterol goals. Arch Intern Med, 2000; 160:459–467.
14.
SloanKI, SalesAE, WillemsJPet al.Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results ≤100mg/dl among patients who had coronary events (Northwest VA Network Study)Am J Cardiol, 2001; 88:1143–1146.
15.
FordES, MokdadAH, GilesWH, MensahGA. Serum total cholesterol concentrations and awareness, treatment and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey. 1999–2000. Circulation, 2003; 107:2185–2189.
16.
OlsonKI, TsuyukiRT. Patients' achievement of cholesterol targets: a cross-sectional evaluation. Am J Prev Med, 2003; 25:339–342.
17.
OlsonKI, BungardTI, TsuyukiRT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy, 2001; 21:807–817.
18.
NashDT. Dyslipidemia: time to treat as seriously as hypertension. Consultant, 1997; 37:1915–1923.
19.
AlfonsoNM, NassifG, AranhaAN, DeLorB, CardozoLJ. Low-density lipoprotein cholesterol goal attainment among high-risk patients: does a combined intervention targeting patients and providers work?Am J Manag Care, 2006; 12:589–594.
20.
MoscaL, LinfanteAH, BenjaminEJet al.National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation, 2005; 111:499–510.
21.
RodondiN, PengT, KarterAJet al.Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med, 2006; 144:475–484.
BurtonWN, HoyDA, StephensM. A computer-assisted health care cost management system. J Occup Med, 1991; 33:268–271.
24.
BurtonWN, ChenC-Y, ContiDJ, SchultzAB, EdingtonDW. The value of the Periodic Executive Health Examination: experience at Bank One and summary of the literature. J Occup Environ Med, 2002; 44:737–744.
25.
OsterbergL, BlaschkeT. Adherence to medication. N Engl J Med, 2005; 353:487–497.
26.
ClarkDO, von KorffM, SaundersK, BaluchWM, SimonGE. A chronic disease score with empirically derived weights. Med Care, 1995; 33:783–795.
27.
BarrattA, ReznikR, IrwigLet al.Worksite cholesterol screening and dietary intervention: the Staff Healthy Heart Project. Steering committee. Am J Public Health, 1994; 84:779–782.
28.
FitzgeraldST, GibbensS, AgnewJ. Evaluation of referral completion after a workplace cholesterol screening program. Am J Prev Med, 1991; 7:335–340.
29.
WangJS, CarsonEC, LapaneKL, EatonCB, GansKM, LasaterTM. The effect of physician office visits on CHD risk factor modification as part of a worksite cholesterol screening program. Prev Med, 1999; 28:221–228.
30.
HartmanTJ, HimesJH, McCarthyPR, KushiLH. Effects of a low-fat, worksite intervention on blood lipids and lipoproteins. J Occup Environ Med, 1995; 37:690–696.
31.
GlasgowRE, TerborgJR, StryckerLA, BolesSM, HollisJF. Take Heart II: replication of a worksite health promotion trial. J Behav Med, 1997; 20:143–161.
32.
SchedlbauerA, Schroeder, FaheyT. How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials. Fam Pract, 2007; 24:380–387.
33.
SchneeweissS, PatrickAR, MaclureM, DormuthCR, GlynnRJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction; a population-based natural experiment. Circulation, 2007; 115:2128–2135.
34.
HertzRP, McDonaldM, UngerAN, LustikMB. Racial and ethnic disparities in the prevalence and management of cardiovascular risk factors in the United States workforce. J Occup Environ Med, 2007; 49:1165–1175.
35.
LeeJK, GraceKA, TaylorAJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. JAMA, 2006; 296:2563–2571.
36.
PegusC, BazzarraTL, BrownJS, MenzinJ. Effect of the Heart at Work Program on awareness of risk factors, self-efficacy, and health behaviors. J Occup Environ Med, 2002; 44:228–236.
37.
BlochMJ, ArmstronDS, DettlingL, HardyA, CaterinoK, BarrieS. Partners in lowering cholesterol: comparison of a multidisciplinary education program, monetary incentives, or usual care in the treatment of dyslipidemia identified among employees. J Occup Environ Med, 2006; 48:675–681.
38.
AldanaSG, GreenlawR, DiehlHA, EnglertH, JacksonR. Impact of the Coronary Health Improvement Project (CHIP) on several employee populations. J Occup Environ Med, 2002; 44:831–839.
39.
AldanaSG, GreenlawRL, DiehlHA, SalbergA, MerrillRM, OhmineS. The effects of a worksite chronic disease prevention program. J Occup Environ Med, 2005; 47:558–564.
40.
SongX, HuseD, WilliamsS, BorokG, McDonoughK, OzminkowskiR. A projection of the impact of lipid-lowering rherapy on high-risk employee disability and medical costs. J Occup Environ Med, 2006; 48:1014–1022.
41.
BatalHA, KrantzMJ, DaleRA, MehlerPS, SteinerJF. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res, 2007; 7:175–180.
42.
GibsonTB, MarkTL, AxelsenK, BaserO, RubleeDA, McGuiganKA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care, 2006; 12:SP11–SP19.
43.
PedanA, VarastehL, SchneeweissS. Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J Manag Care Pharm, 2007; 13:487–496.
44.
McGinnisB, OlsonKL, MagidDet al.Factors related to adherence to statin therapy. Ann Pharmacother, 2007; 41:1805–1811.
45.
MannDM, AllegranteJP, NatarajanS, HalmEA, CharlsonM. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther, 2007; 21:311–316.
46.
BurtonWN, ChenCY, SchultzAB, EdingtonDW. The association between a tiered pharmacy benefit plan and medication usage, health status, and disability absence days—one employer's experience. J Occup Environ Med, 2008; 50:1176–1184.
